The Efficacy and Safety of TAF vs Other NAs in Patients With LVL
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
Patients with chronic hepatitis B should maximize the inhibition of HBV replication, which
could reduce the incidence of liver cancer and liver disease-related complications. However,
after 96 weeks of treatment with the first-line drugs, entecavir or tenofovir disoproxil
fumarate, a certain proportion of patients still had low levels of HBV replication. Tenofovir
alafenamide fumarate is a newly marketed anti-hepatitis B drug that is currently considered
to be non-inferior to tenofovir disoproxil fumarate and safer bone and renal effects.
Therefore, this research was put forward to investigate whether tenofovir alafenamide
fumarate replacement for hepatitis B had a higher virological response rate and safety in
patients with low levels of virus after 48 weeks of treatment with entecavir and tenofovir
disoproxil fumarate.